Lucid Diagnostics (LUCD) to Release Earnings on Wednesday

Lucid Diagnostics (NASDAQ:LUCDGet Rating) will be announcing its earnings results after the market closes on Wednesday, May 11th. Investors that are interested in participating in the company’s conference call can do so using this link.

Lucid Diagnostics (NASDAQ:LUCDGet Rating) last issued its earnings results on Monday, March 28th. The company reported ($0.32) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.20) by ($0.12). On average, analysts expect Lucid Diagnostics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Shares of LUCD stock opened at $2.21 on Wednesday. The business has a 50 day simple moving average of $2.98. Lucid Diagnostics has a fifty-two week low of $2.01 and a fifty-two week high of $13.52.

A number of equities research analysts have weighed in on LUCD shares. Zacks Investment Research downgraded Lucid Diagnostics from a “hold” rating to a “sell” rating in a report on Tuesday, April 26th. Needham & Company LLC lowered their target price on Lucid Diagnostics from $13.00 to $7.00 and set a “buy” rating for the company in a report on Tuesday, March 29th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Lucid Diagnostics in a report on Friday, February 4th. Canaccord Genuity Group decreased their price objective on Lucid Diagnostics from $18.00 to $12.00 and set a “buy” rating for the company in a report on Tuesday, March 29th. Finally, BTIG Research decreased their price objective on Lucid Diagnostics from $14.00 to $6.00 in a report on Tuesday, April 5th. One analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. Based on data from MarketBeat, Lucid Diagnostics presently has an average rating of “Buy” and an average target price of $13.14.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in LUCD. Bank of America Corp DE bought a new stake in shares of Lucid Diagnostics during the fourth quarter valued at approximately $29,000. Charles Schwab Investment Management Inc. purchased a new position in shares of Lucid Diagnostics during the fourth quarter valued at approximately $59,000. Virtu Financial LLC purchased a new position in shares of Lucid Diagnostics during the fourth quarter valued at approximately $61,000. Susquehanna International Group LLP purchased a new position in shares of Lucid Diagnostics during the fourth quarter valued at approximately $71,000. Finally, Invesco Ltd. purchased a new position in shares of Lucid Diagnostics during the fourth quarter valued at approximately $93,000. Hedge funds and other institutional investors own 8.84% of the company’s stock.

Lucid Diagnostics Company Profile (Get Rating)

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma.

Featured Stories

Receive News & Ratings for Lucid Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lucid Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.